Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242580 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 111
- Enrollment target
NCT00242580 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 111 participants.
The verdict
NCT00242580, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 111 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration. The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib added as an intravitreal injection.
Interventions
- DRUG Triamcinolone acetonide
- DRUG Verteporfin photodynamic therapy
- DRUG Pegaptanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00242580
The ClinicalTrials.gov registry entry for NCT00242580 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Triamcinolone acetonide is the first listed.
NCT00242580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00242580 about?
NCT00242580 is a clinical study titled "A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib". To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration. The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib added as an intravitreal injection.
What is the current status of trial NCT00242580?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 2005-09.
What interventions are being tested in trial NCT00242580?
The interventions under investigation include: Triamcinolone acetonide (DRUG), Verteporfin photodynamic therapy (DRUG), Pegaptanib (DRUG).
Who is sponsoring clinical trial NCT00242580?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.